Pneumonia Therapeutics Market Updates : Predicted to Attain USD 25.54 Billion by 2030
Pneumonia Therapeutics Market
Rise in incidence of pneumonia acts as a key driving force of the global pneumonia therapeutics market.
WILMINGTON, DELAWARE , UNITED STATES, May 27, 2024 /EINPresswire.com/ -- The global pneumonia therapeutics market size was valued at $12,293.9 million in 2020, and is projected to reach $25,546.8 million by 2030, registering a CAGR of 8.5% from 2021 to 2030.
• CAGR: 8.5%
• Current Market Size: USD 12.29 Billion
• Forecast Growing Region: APAC
• Largest Market: North America
• Projection Time: 2021- 2030
• Base Year: 2021
𝑹𝒆𝒒𝒖𝒆𝒔𝒕 𝑺𝒂𝒎𝒑𝒍𝒆 𝑪𝒐𝒑𝒚 𝒐𝒇 𝒕𝒉𝒆 𝑹𝒆𝒑𝒐𝒓𝒕 𝑯𝒆𝒓𝒆 https://www.alliedmarketresearch.com/request-sample/A11230
The global pneumonia therapeutics market is experiencing significant growth due to several factors: a surge in pneumonia cases, an aging population with weaker immune systems, increased incidence and spending on community-acquired pneumonia, and a rise in product launches. However, the high cost of pneumonia treatments is a limiting factor. Nonetheless, the emergence of novel viruses targeting the respiratory system presents new opportunities for growth in the coming years.
In 2020, the prevention vaccines segment dominated the market, holding over two-thirds of the total market share. This segment is anticipated to maintain its leading position throughout the forecast period. Conversely, the treatment drugs segment is projected to experience the highest compound annual growth rate (CAGR) of 9.6% from 2021 to 2030.
During the forecast period, North America is expected to hold a substantial share of the global pneumonia therapeutics market. This growth is driven by an increase in healthcare spending and a growing patient population in the region. Additionally, Asia-Pacific is forecasted to experience the fastest compound annual growth rate (CAGR) during this period, primarily due to its large patient population and rapid infrastructural advancements. Furthermore, the rise in government investments in research and development of medications is anticipated to further fuel market growth in the Asia-Pacific region.
𝐃𝐨 𝐘𝐨𝐮 𝐇𝐚𝐯𝐞 𝐀𝐧𝐲 𝐐𝐮𝐞𝐫𝐲 𝐎𝐫 𝐒𝐩𝐞𝐜𝐢𝐟𝐢𝐜 𝐑𝐞𝐪𝐮𝐢𝐫𝐞𝐦𝐞𝐧𝐭? 𝐀𝐬𝐤 𝐭𝐨 𝐎𝐮𝐫 𝐈𝐧𝐝𝐮𝐬𝐭𝐫𝐲 𝐄𝐱𝐩𝐞𝐫𝐭: https://www.alliedmarketresearch.com/purchase-enquiry/11595
𝐊𝐞𝐲 𝐁𝐞𝐧𝐞𝐟𝐢𝐭𝐬 𝐅𝐨𝐫 𝐒𝐭𝐚𝐤𝐞𝐡𝐨𝐥𝐝𝐞𝐫𝐬
The study provides an in-depth analysis of the pneumonia therapeutics market size along with the current trends and future estimations to elucidate the imminent investment pockets.
The report covers the pneumonia therapeutics market analysis from 2020 to 2030, which is expected to enable the stakeholders to capitalize on the prevailing opportunities in the market.
A comprehensive analysis of factors that drive and restrain the growth of the pneumonia therapeutics market is provided.
The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook and pneumonia therapeutics market growth.
𝐊𝐄𝐘 𝐅𝐈𝐍𝐃𝐈𝐍𝐆𝐒 𝐎𝐅 𝐓𝐇𝐄 𝐒𝐓𝐔𝐃𝐘
Depending on therapeutics, the treatment drugs segment held largest share in the global pneumonia therapeutics market in 2020.
On the basis of distribution channel, the research experienced the highest revenue in 2020, and is expected to continue to grow throughout the forecast period.
By end user, the hospitals & diagnostic laboratories garnered the largest pneumonia therapeutics market share in 2020, and is expected to remain dominant throughout the forecast period.
Region wise, LAMEA is expected to experience growth at the highest rate, registering a CAGR of 12.0% during the forecast period.
𝐊𝐞𝐲 𝐌𝐚𝐫𝐤𝐞𝐭 𝐏𝐥𝐚𝐲𝐞𝐫𝐬
Abbott Laboratories
Bayer AG
Eli Lilly & Company
GlaxoSmithKline PLC.
Lupin Pharmaceuticals, Inc.
Merck KGaA
Novartis AG
Pfizer, Inc.
Sanofi S.A.
Teva Pharmaceuticals Industries Limited
𝐓𝐫𝐞𝐧𝐝𝐢𝐧𝐠 𝐑𝐞𝐩𝐨𝐫𝐭𝐬 𝐢𝐧 𝐇𝐞𝐚𝐥𝐭𝐡𝐜𝐚𝐫𝐞 𝐈𝐧𝐝𝐮𝐬𝐭𝐫𝐲 (𝐁𝐨𝐨𝐤 𝐍𝐨𝐰 𝐰𝐢𝐭𝐡 10% 𝐃𝐢𝐬𝐜𝐨𝐮𝐧𝐭):
𝐎𝐩𝐡𝐭𝐡𝐚𝐥𝐦𝐢𝐜 𝐎𝐑 𝐌𝐢𝐜𝐫𝐨𝐬𝐜𝐨𝐩𝐞𝐬 𝐦𝐚𝐫𝐤𝐞𝐭 https://www.alliedmarketresearch.com/ophthalmic-operating-room-microscope-market-A10607
𝐒𝐭𝐞𝐫𝐢𝐥𝐢𝐳𝐚𝐭𝐢𝐨𝐧 𝐒𝐞𝐫𝐯𝐢𝐜𝐞𝐬 𝐌𝐚𝐫𝐤𝐞𝐭 https://www.alliedmarketresearch.com/sterilization-services-market-A07513
David Correa
Allied Market Research
+ 18007925285
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn
Other
EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.
